A key chart suggests further gains in the chemical giant are possible, but be aware that it could explore lower levels of October again.
Biogen shares rose 15% Friday following upbeat results from an Alzheimer's drug test.
What was once a red and blue issue has now attracted a growing set of proponents from both sides of the aisle.
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.